Literature DB >> 24236446

Proton pump inhibitors as a possible cause of vitiligo: an in vivo and in vitro study.

J M Shin1, J Y Lee, D Y Lee, T Y Yoon, J C Lee, E H Lim, K C Sohn, Y H Lee, M Im, Y J Seo, C D Kim, J H Lee, Y Lee.   

Abstract

BACKGROUND: Vitiligo is an acquired depigmentation disorder of melanocytes. Recently, some clinical reports have suggested that proton pump inhibitors (PPIs) may worsen vitiligo, but their effects on melanocytes have yet to be elucidated.
OBJECTIVE: We investigated the effect of PPIs on melanogenesis in vivo and in vitro.
METHODS: We examined the effect of PPIs on melanogenesis in B16 murine melanoma cells by measuring melanin content and tyrosinase (TYR) activity. TYR and tyrosinase-related protein-1 (TRP-1) were monitored by western blotting. Finally, a PPI was applied to zebrafish embryos to investigate its in vivo effect on pigmentation.
RESULTS: In agreement with our clinical experience of worsened vitiligo after PPI treatment, PPIs decreased both melanin content and TYR activity. Western blotting showed that PPIs decreased TYR and TRP-1 protein levels. In the zebrafish test, PPIs inhibited body pigmentation in a dose-dependent manner.
CONCLUSION: These results suggest that the functional inhibition of melanization by PPIs may induce or aggravate vitiligo lesions in genetically predisposed patients.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24236446     DOI: 10.1111/jdv.12317

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

1.  Proton pump inhibitors decrease melanogenesis in melanocytes.

Authors:  Seung-Hwa Baek; Sang-Han Lee
Journal:  Biomed Rep       Date:  2015-07-17

2.  Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking.

Authors:  Mary S Matsui; Michael J Petris; Yoko Niki; Nevena Karaman-Jurukovska; Neelam Muizzuddin; Masamitsu Ichihashi; Daniel B Yarosh
Journal:  J Invest Dermatol       Date:  2014-10-22       Impact factor: 8.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.